IMGN News and Press, ImmunoGen Inc. From 09/28/23

Data Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual Congress ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of ...

2023-09-20 11:40:13 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group –  Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  &...

2023-09-18 06:42:01 ET More on ImmunoGen Seeking Alpha’s Quant Rating on ImmunoGen Historical earnings data for ImmunoGen Financial information for ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? Immun...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer. "We are excited to have Lauren join our team and believe th...

2023-09-13 12:18:15 ET ImmunoGen's ( NASDAQ: IMGN ) shares rose +4.82% to $16.20 on Wednesday after J.P. Morgan upgraded the company to 'overweight' from 'neutral' citing the ongoing U.S. launch of Elahere in platinum-resistant ovarian cancer, which the brokerage belie...

2023-08-31 17:19:31 ET Gainers: Nutanix ( NTNX ) +13% . Intuitive Machines ( LUNR ) +9% . NGM Biopharmaceuticals ( NGM ) +7% . Vaxxinity ( VAXX ) +5% . NANO-X IMAGING ( NNOX ) +5% . Losers: Jet ( JTAI ) -4% . ...

2023-08-29 13:45:03 ET Summary Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as ...

2023-08-28 07:12:00 ET More on ImmunoGen, Takeda, etc. ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ELAHERE Has Likely Blockbuster Potential ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential Takeda: Upside Ca...

ImmunoGen to Receive $34 Million 1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Payments as well as Double-Digit Royalties Collaboration Further Supports Strategy to Bring ELAHERE to Eligible Patients with Folate ...

2023-08-17 06:40:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech...